MedPage Today, January 31, 2018. The FDA is trying to find a streamlined approach to the opioid crisis. Dr. Zuckerman urged the FDA to include education on “abuse deterrent” within its Risk Evaluation and Mitigation Strategies since the term is often misinterpreted to mean the drug is less addictive.
Read More »We’re In The News
As a respected nonprofit health research center, our views are often quoted in the media, including newspapers, magazines, TV, radio, and websites. We also write articles and blogs for a number of different and highly respected newspapers, magazines, and popular websites, and we are published in prestigious medical journals and health policy publications. We frequently express our policy views in letters to government officials and public comments to federal agencies and we sometimes release statements or press releases on newsworthy issues.
Please e-mail info@center4research.org or call 202-223-4000 with your inquiries. We can assist you with scheduling interviews with the NCHR President, Dr. Diana Zuckerman, and other experts on our staff.
Trump Targets Drug Prices, Right-to-Try in State of the Union
AJMC Newsroom, January 31, 2018. At the State of the Union, Trump vowed to bring down the high cost of prescription drugs and called on Congress to pass the Right to Try bill. This bill might end up doing more harm than good for patients.
Read More »Big Pharma Greets Hundreds of Ex-Federal Workers at the ‘Revolving Door’
Kaiser Health News, January 25, 2018. A Kaiser Health News analysis shows that hundreds of people have glided through the “revolving door” that connects the drug industry to Capitol Hill and to the Department of Health and Human Services. Experts say the cozy relationships don’t necessarily mean congressional staffers do favors for lobbyists they know, but the access doesn’t hurt.
Read More »The Problem with Medical Device Approval
MedShadow, January 16, 2018. To get FDA approval for a medical device, a company needs to say that its device is “substantially equivalent” to an existing one. Devices might be easily approved without further safety and effectiveness studies.
Read More »Essure Device Stirring Trouble on the Hill
MedPage Today, November 14, 2017. After much controversy, Essure permanent contraceptive is supposed to be studied by Bayer and compared to “tubes tied.” Is the study delayed?
Read More »